Diversification of global supply chains, drug stockpiling, and boosting Europe's capacity to produce and innovate in the manufacturing of critical medicines and their ingredients are among the topics to be addressed by the European Commission’s forthcoming Critical Medicines Alliance.
Moves to set up a “Critical Medicines Alliance” in the EU to tackle the problem of critical medicines shortages by changing the way the bloc produces and procures drugs and reinforces its security of supply have stepped up a gear.
Drug companies, national authorities and many other pharmaceutical sector stakeholders have been invited to express their interest in joining the...
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
A total of 748 key medicines are now affected by the four-month stock requirement, compared with 422 in 2021.
The UK will require all antibiotic manufacturers looking to apply for funding under its subscription payment model to demonstrate they are meeting waste discharge standards in a bid to reduce antimicrobial resistance.
Joint clinical assessment reports must be descriptive rather than reach definitive conclusions, and must not interfere with national decision making processes, according to new EU guidance.
Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.
The agency’s plan for advanced manufacturing seeks more harmonization, while also seeking to codify internal practices with guidance and training.
